Aigen Investment Management LP Acquires New Shares in TransMedics Group, Inc. (NASDAQ:TMDX)

Aigen Investment Management LP bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 3,330 shares of the company’s stock, valued at approximately $523,000.

Several other large investors have also recently bought and sold shares of TMDX. International Assets Investment Management LLC acquired a new position in shares of TransMedics Group during the second quarter worth $47,000. USA Financial Formulas bought a new position in TransMedics Group during the 3rd quarter worth $55,000. J.Safra Asset Management Corp raised its position in TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after purchasing an additional 383 shares during the last quarter. Signaturefd LLC lifted its holdings in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the period. Finally, Farther Finance Advisors LLC grew its position in shares of TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after buying an additional 316 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at TransMedics Group

In other news, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares in the company, valued at $3,714,902.10. This trade represents a 32.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,958 shares of company stock worth $5,230,528. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Price Performance

TMDX stock opened at $88.36 on Friday. TransMedics Group, Inc. has a 1 year low of $63.85 and a 1 year high of $177.37. The stock has a market capitalization of $2.97 billion, a PE ratio of 94.00 and a beta of 2.08. The company’s 50-day moving average is $127.92 and its 200-day moving average is $139.56. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s revenue was up 63.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.12) EPS. Equities research analysts expect that TransMedics Group, Inc. will post 1.07 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group reduced their price objective on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th. Stephens lifted their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. dropped their target price on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a report on Tuesday, October 29th. Finally, Needham & Company LLC decreased their price target on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $144.80.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.